grace capital Has $8.35 Million Stock Position in Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Share on StockTwits

grace capital lowered its stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 2.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 311,132 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the period. Portola Pharmaceuticals accounts for 8.4% of grace capital’s holdings, making the stock its 2nd biggest position. grace capital owned about 0.40% of Portola Pharmaceuticals worth $8,345,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in PTLA. Next Capital Management LLC bought a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $27,000. Point72 Hong Kong Ltd bought a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $31,000. Tower Research Capital LLC TRC bought a new stake in shares of Portola Pharmaceuticals during the 3rd quarter worth approximately $42,000. Cornerstone Advisors Inc. raised its stake in shares of Portola Pharmaceuticals by 34.6% during the 3rd quarter. Cornerstone Advisors Inc. now owns 1,801 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 463 shares in the last quarter. Finally, Valley National Advisers Inc. raised its stake in shares of Portola Pharmaceuticals by 32.0% during the 2nd quarter. Valley National Advisers Inc. now owns 4,046 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 981 shares in the last quarter.

In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the director now directly owns 18,194 shares in the company, valued at $545,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.50% of the stock is currently owned by company insiders.

PTLA has been the topic of a number of recent analyst reports. William Blair reissued a “buy” rating on shares of Portola Pharmaceuticals in a report on Friday, August 9th. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a report on Friday, November 8th. They set a “neutral” rating and a $35.00 target price on the stock. Morgan Stanley began coverage on Portola Pharmaceuticals in a report on Thursday, September 5th. They set a “hold” rating and a $37.00 target price on the stock. Citigroup decreased their price objective on Portola Pharmaceuticals from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Finally, BidaskClub lowered Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $38.75.

Shares of PTLA stock traded up $0.54 on Wednesday, hitting $28.33. 571,421 shares of the company’s stock were exchanged, compared to its average volume of 1,122,011. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.88 and a quick ratio of 5.85. The stock has a market cap of $2.18 billion, a P/E ratio of -5.65 and a beta of 2.07. Portola Pharmaceuticals Inc has a 12 month low of $14.81 and a 12 month high of $37.95. The company has a 50 day moving average of $28.53 and a 200 day moving average of $28.03.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.14. The firm had revenue of $36.80 million during the quarter, compared to the consensus estimate of $34.64 million. Portola Pharmaceuticals had a negative return on equity of 282.04% and a negative net margin of 275.13%. The business’s quarterly revenue was up 159.2% on a year-over-year basis. During the same period last year, the company earned ($1.08) earnings per share. Sell-side analysts predict that Portola Pharmaceuticals Inc will post -3.05 EPS for the current fiscal year.

Portola Pharmaceuticals Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

See Also: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.